Senti Biosciences (SNTI) Cash from Financing Activities (2021 - 2025)

Senti Biosciences has reported Cash from Financing Activities for 5 years, with the latest figure at $11.0 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities fell 78.48% year-over-year to $11.0 million; the trailing twelve-month figure through Dec 2025 stood at $11.8 million (down 78.11% YoY), and the FY2025 full-year result was $11.8 million, down 78.11% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $11.0 million, up from $124000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $232.0 million in Q2 2021, with the low at -$485000.0 in Q3 2022.
• Average Cash from Financing Activities over 5 years is $51.8 million, with a median of $876000.0 recorded in 2022.
• Year-over-year, Cash from Financing Activities plunged 100.21% in 2022 and jumped 10708.7% in 2024.
• Tracing SNTI's Cash from Financing Activities over 5 years: stood at $232.0 million in 2021, then sank by 99.62% to $876000.0 in 2022, then sank by 36.53% to $556000.0 in 2023, then surged by 9124.82% to $51.3 million in 2024, then slumped by 78.48% to $11.0 million in 2025.
• The last three Cash from Financing Activities figures came in at $11.0 million (Q4 2025), $124000.0 (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.

Peer Comparison